Micurx Pharmaceuticals, Inc.

Other

Merck Sharp + Dohme Corp.

Shanghai Micro Electronics Equipment (group) Co., Ltd.

Shanghai Micurx Pharmaceutical Co., Ltd.

Fudan University

Xinghai Wang

Mikhail Fedorovich Gordeev

Jinqian Liu

Zhengyu Yuan

Joseph P Vacca

Hao Wu

Craig Alan Coburn

Hao Wang

Bin Hu

John A McCauley

Kun Liu

Fei Sun

Richard Soll

Jian Zhu

Steven W Ludmerer

Bin Zhong

Mingwei Zheng

Hongzhuan Chen

Haijiang Wang

Zhuibai Qiu

Qiong Xie

Zheng Xia

Meiyan Lu

Xueliang Zhang

Man Yan

Mingbo Yuan

Chengren Zhang

John A Mccauley

The present invention relates to a pharmaceutical crystal of contezolid acefosamil, a preparation method therefor, and uses thereof. The present invention also relates to a crystal or crystal complex of formula I, wherein R is selected from hydrogen, sodium or a mixture thereof in any ratio.

Pharmaceutical crystal of contezolid acefosamil, preparation method therefor, and uses thereof

A device and method for measuring amplitude of a scanning mirror are disclosed. The device includes a light source () for outputting an optical signal; a diaphragm () for modifying size and shape of a light spot of the optical signal output by the light source (); a scanning mirror retainer for placing a scanning mirror () to be measured, the scanning mirror, after being retained, being able to periodically reflect the optical signal; a photoelectric sensor () including three or more sensing elements and configured to detect and collect the optical signal reflected by the scanning mirror (); and a signal acquisition and processing unit () for processing a signal collected by the photoelectric sensor () to derive an amplitude of the scanning mirror (). Therefore, it is possible to characterize the scanning mirror () before the scanning mirror () is used, determining performance of the scanning mirror ().

Apparatus and method for measuring amplitude of scanning reflector

The present invention provides antimicrobial polymyxin compounds of the following formula I: or pharmaceutically acceptable salts, hydrates, or solvates thereof that are antibacterial agents, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.

Antimicrobial polymyxins for treatment of bacterial infections

The present invention provides certain water-soluble O-carbonyl phosphoramidate prodrugs of the following formula I: or pharmaceutically acceptable salts thereof that are therapeutic or antibacterial agents, pharmaceutical compositions containing them, methods for their use, and reagents and methods for preparing these compounds.

Water-soluble O-carbonyl phosphoramidate prodrugs for therapeutic administration

The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. 

Inhibitors of hepatitis C virus replication

Provided herein are antimicrobial tricyclic boron compounds of the following formula I: or pharmaceutically acceptable salts, complexes, or tautomers thereof that are antibacterial agents, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.

Tricyclic boron compounds for antimicrobial therapy

The present invention belongs to pharmaceutical field. It relates to a novel family of bivalent (&#x2212;)-meptazinol compounds and/or their salts, as well as the preparation and utilization of the compounds in the treatment of neurodegenerative disorders and dementias such as Alzheimer's Disease (AD). In the present invention, bivalent (&#x2212;)-meptazinol compounds were synthesized, from the starting material (&#x2212;)-meptazinol, successively by N-demethylation forming (&#x2212;)-nor-meptazinol and then by acylation with &#x3b1;,&#x3c9;-alkanediacyl dihalides or alkylation with &#x3b1;,&#x3c9;-dihaloalkanes. Results from in vitro cholinesterase inhibiting test and AChE-induced A&#x3b2; aggregation test demonstrated that the bivalent (&#x2212;)-meptazinol compounds and/or their salts were novel bivalent inhibitors of both AChE and A&#x3b2; aggregation. The most potent compound inhibited both AChE and BChE at nM level, which was 10000 and 1500 times more potent than (&#x2212;)-MEP hydrochloride, respectively. It inhibited AChE-induced A&#x3b2; aggregation by a factor of 2 compared with propidium.

Bivalent (&#x2212;)-meptazinol compounds and/or their salts, and their preparation and futilization

Growing community of inventors

Shanghai, China

Xinghai Wang